IBM and Nvidia move quantum processors into supercomputing workflows
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
Quantum / NEWS BRIEF
A peer-reviewed experiment used a single-shot frequency check and real-time feedback to cut average gate error from about 0.14% to 0.065% on one unstable superconducting qubit.
Researchers from the University of Regensburg and collaborators tested a superconducting qubit whose resonance frequency switched between two known values because of a material defect. Their controller used one single-shot measurement to identify the active frequency, then adjusted the control frame before the following quantum operations. The peer-reviewed Applied Physics Reviews paper describes an estimation bandwidth of approximately 136 kilohertz.
The University of Regensburg reports that average gate error fell from approximately 0.14% without feedback to 0.065% with feedback, a reduction of about 54%. Relative to the largest uncorrected error observed, the reduction reached 77%, matching the result highlighted in the paper abstract. The experiment ran on a superconducting circuit at the Israeli Quantum Computing Center with measurement results processed in real time.
The method applies under specific conditions: the possible frequencies must be known and distinguishable, and the selected frequency must remain stable long enough for the correction to help. The published work demonstrates adaptive control on one bistable qubit; it does not show a processor-wide error reduction, fault tolerance or quantum advantage. Its importance is a simple feedback strategy for a concrete material-defect problem that could remain relevant as larger superconducting arrays are built.
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
OpenAI has released healthcare-focused computer-use capabilities across its API and clinical products, with configurable approvals, audit logs and new performance results that remain provider-reported.